Pharma BD Deal Intelligence
The Synagis asset itself faded and was discontinued by 2025, but the bundled nirsevimab (Beyfortus) royalty right turned out to be the deal's true value driver, generating a fast-growing, high-margin US royalty stream through the 2030s.
Full analysis, sources & comparables →AstraZeneca's largest divestiture in five years; Jefferies (Sobi advisor) pegs total deal value at $2.3B once Synagis sales milestones, BLA submission payment…
Sobi confirmed it would discontinue Synagis in the US following Beyfortus's broad-label approval — the original franchise BMS Sobi acquired is now obsolete,…
Sobi FY2025: Synagis revenue collapsed (~SEK 89M for season vs SEK 520M a year earlier in Q1 alone) ahead of the Dec 31, 2025 US withdrawal, while the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sobi acquired US rights to AstraZeneca's RSV antibody Synagis (palivizumab) plus a US profit share on the next-gen MEDI8897 (nirsevimab) in November 2018 for $1.5B upfront ($1.0B cash + $500M Sobi shares to AstraZeneca), plus up to $470M in Synagis sales milestones from 2026, $175M for MEDI8897 BLA submission, ~$110M in MEDI8897 profit/development milestones, and $20M/yr 2019-2021 (total deal value up to ~$2.3B). AstraZeneca's largest divestiture in 5 years. Post-close, the structure evolved as anticipated: in April 2023, ahead of the Beyfortus (nirsevimab) FDA approval, Sobi restructured the arrangement — converting its US nirsevimab profit share into a tiered royalty (25% at launch, rising 2025-2028 to 30-35% of US net sales), paying Sanofi $66M for prior R&D and terminating the AstraZeneca participation agreement for $15M. Beyfortus's July 2023 broad-label approval and Merck's clesrovimab (Enflonsia, 2025) then displaced palivizumab, and Sobi withdrew Synagis from the US market effective December 31, 2025 (FY2025 Synagis revenue had collapsed to ~SEK 89M while the Beyfortus royalty contributed ~SEK 849M), validating AstraZeneca's exit timing while leaving Sobi the durable nirsevimab royalty tail.
The Synagis asset itself faded and was discontinued by 2025, but the bundled nirsevimab (Beyfortus) royalty right turned out to be the deal's true value driver, generating a fast-growing, high-margin US royalty stream through the 2030s.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) (this deal) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Madison Dearborn Partners / Ikaria, Inc. | 2013 | $1.6B | 85 |
← Browse all deals · How we score deals
More: 2018 deals · Swedish Orphan Biovitrum AB deals · Respiratory deals